|
Gene: ZFP82 |
Gene summary for ZFP82 |
Gene summary. |
Gene information | Species | Human | Gene symbol | ZFP82 | Gene ID | 284406 |
Gene name | ZFP82 zinc finger protein | |
Gene Alias | ZNF545 | |
Cytomap | 19q13.12 | |
Gene Type | protein-coding | GO ID | GO:0006139 | UniProtAcc | D3Y299 |
Top |
Malignant transformation analysis |
Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
Malignant transformation involving gene list. |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
284406 | ZFP82 | HCC1 | Human | Liver | HCC | 4.32e-24 | 2.68e+00 | 0.5336 |
284406 | ZFP82 | HCC2 | Human | Liver | HCC | 1.42e-29 | 2.39e+00 | 0.5341 |
284406 | ZFP82 | HCC5 | Human | Liver | HCC | 9.75e-34 | 2.48e+00 | 0.4932 |
284406 | ZFP82 | male-WTA | Human | Thyroid | PTC | 2.03e-06 | 4.03e-02 | 0.1037 |
284406 | ZFP82 | PTC01 | Human | Thyroid | PTC | 8.76e-07 | 5.17e-02 | 0.1899 |
284406 | ZFP82 | PTC04 | Human | Thyroid | PTC | 1.63e-02 | 3.42e-02 | 0.1927 |
284406 | ZFP82 | PTC06 | Human | Thyroid | PTC | 4.31e-02 | 7.02e-02 | 0.2057 |
284406 | ZFP82 | PTC07 | Human | Thyroid | PTC | 1.31e-09 | 7.27e-02 | 0.2044 |
284406 | ZFP82 | ATC12 | Human | Thyroid | ATC | 1.87e-02 | 4.69e-02 | 0.34 |
284406 | ZFP82 | ATC13 | Human | Thyroid | ATC | 2.57e-33 | 5.60e-01 | 0.34 |
284406 | ZFP82 | ATC2 | Human | Thyroid | ATC | 3.00e-05 | 5.14e-01 | 0.34 |
284406 | ZFP82 | ATC4 | Human | Thyroid | ATC | 5.63e-03 | 5.60e-02 | 0.34 |
284406 | ZFP82 | ATC5 | Human | Thyroid | ATC | 1.11e-34 | 6.21e-01 | 0.34 |
Page: 1 |
Transcriptomic changes along malignancy continuum. |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
Figure of enriched GO biological processes. |
Tissue | Disease Stage | Enriched GO biological Processes |
Oral cavity | OSCC | |
Oral cavity | LP | |
Oral cavity | EOLP | |
Oral cavity | NEOLP | |
Esophagus | HGIN |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
Enriched GO biological processes. |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
Page: 1 |
Enriched KEGG pathways. |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
Page: 1 |
Top |
Cell-cell communication analysis |
Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
Annotation of somatic variants for genes involved in malignant transformation |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
ZFP82 | SNV | Missense_Mutation | c.592N>C | p.Tyr198His | p.Y198H | Q8N141 | protein_coding | deleterious(0.03) | probably_damaging(1) | TCGA-AN-A0AK-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
ZFP82 | SNV | Missense_Mutation | c.1423N>A | p.Glu475Lys | p.E475K | Q8N141 | protein_coding | deleterious(0.05) | probably_damaging(0.999) | TCGA-AR-A0TR-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | tamoxiphen | SD | |
ZFP82 | SNV | Missense_Mutation | c.713N>A | p.Gly238Asp | p.G238D | Q8N141 | protein_coding | tolerated(0.08) | benign(0.339) | TCGA-BH-A18G-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
ZFP82 | SNV | Missense_Mutation | novel | c.90G>C | p.Leu30Phe | p.L30F | Q8N141 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-E2-A1IN-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Hormone Therapy | arimidex | SD |
ZFP82 | SNV | Missense_Mutation | novel | c.1271N>A | p.Cys424Tyr | p.C424Y | Q8N141 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-LD-A74U-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Chemotherapy | taxotere | SD |
ZFP82 | insertion | In_Frame_Ins | novel | c.782_783insAAAAAAAAACTACAATCAGTATTCTCT | p.Lys261_Ala262insLysLysAsnTyrAsnGlnTyrSerLeu | p.K261_A262insKKNYNQYSL | Q8N141 | protein_coding | TCGA-AO-A03R-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | doxorubicin | SD | ||
ZFP82 | insertion | Frame_Shift_Ins | novel | c.531_532insACCGAGACTCTGTCTCAAACAAAAAACAAAAA | p.Ala178ThrfsTer131 | p.A178Tfs*131 | Q8N141 | protein_coding | TCGA-AO-A0J9-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | cyclophosphamide | PD | ||
ZFP82 | SNV | Missense_Mutation | c.797N>A | p.Arg266Gln | p.R266Q | Q8N141 | protein_coding | tolerated(0.32) | benign(0.006) | TCGA-C5-A1BK-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD | |
ZFP82 | SNV | Missense_Mutation | novel | c.590C>T | p.Pro197Leu | p.P197L | Q8N141 | protein_coding | tolerated(0.07) | probably_damaging(1) | TCGA-EA-A3HS-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD |
ZFP82 | SNV | Missense_Mutation | c.1576A>C | p.Lys526Gln | p.K526Q | Q8N141 | protein_coding | deleterious(0.03) | benign(0.342) | TCGA-AA-3977-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | SD |
Page: 1 2 3 4 5 6 7 8 9 |
Top |
Related drugs of malignant transformation related genes |
Identification of chemicals and drugs interact with genes involved in malignant transfromation |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
Page: 1 |